Skip to main content

Table 3 Treatment phase indicators

From: Multicentre clinical radiotherapy audit in rectal cancer: results of the IROCA project

INDICATORS ICO-B ICO-G ICO H IPO NO WCO All  
N
(%)
N
(%)
N
(%)
N
(%)
N
(%)
N
(%)
N % P
Patients included in clinical trial 3
(7.5)
0
(0.0)
10
(25.0)
0
(0.0)
1
(4.5)
0
(0.0)
14 6.3 0.000
Long Course Radiotherapy (LCRT) 33
(82.5)
40
(100)
32
(80.0)
31
(79.5)
11
(50.0)
24
(60.0)
171 77.4 0.000
Short Course Radiotherapy (SCRT) 7
(17.5)
0
(0.0)
8
(20.0)
8
(20.5)
11
(50.0)
16
(40.0)
50 22.6 0.000
3DCRT 32
(80.0)
40
(100)
29
(72.5)
4
(10.3)
0
(0.0)
39
(97.5)
144 65.1 0.000
VMAT 8
(20.0)
0
(0.0)
11
(27.5)
2
(5.1)
6
(27.3)
1
(2.5)
28 12.7 0.000
IMRT 0
(0.0)
0
(0.0)
0
(0.0)
33
(84.6)
16
(72.7)
0
(0.0)
49 22.2 0.000
SIB 0
(0.0)
9
(22.5)
10
(25.0)
1
(2.6)
0
(0.0)
1
(2.5)
21 9.5 0.000
Treatment completed in prescription time 20
(50.0)
4
(10.0)
10
(25.0)
36
(92.3)
14
(63.6)
39
(97.5)
123 55.7 0.000
RT treatment interruption 20
(50.0)
36
(90.0)
29
(72.5)
3
(7.7)
8
(36.4)
1
(2.5)
97 43.9 0.000
Treatment interruption: patient reason 4
(20.0)
2
(5.6)
1
(3.4)
0
(0.0)
4
(50.0)
1
(100.0)
12 12.4 0.000
Treatment interruption: center-related 17
(85.0)
35
(97.2)
28
(96.6)
3
(100.0)
5
(62.5)
0
(0.0)
88 90.7 0.001
Treatment compensation for interruptions 0
(0.0)
1
(2.8)
0
(0.0)
0
(0.0)
0
(0.0)
1
(100.0)
2 2.1 0.000
Presented to 2nd MTB 18
(45.0)
20
(50.0)
22
(55.0)
3
(7.7)
1
(4.5)
3
(7.5)
67 30.3 0.000
Restaging MRI 10
(25.0)
28
(70.0)
18
(45.0)
0
(0.0)
8
(36.4)
37
(92.5)
101 45.7 0.000
Restaging TNM 4
(10.0)
20
(50.0)
9
(22.5)
0
(0.0)
0
(0.0)
29
(72.5)
62 28.1 0.000
Presented to MTB after surgery 2
(5.0)
23
(57.5)
30
(75.0)
28
(71.8)
5
(22.7)
39
(97.5)
127 57.5 0.000